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Abstract
Aims/hypothesis We investigated whether variation in
MTNR1B, which was recently identified as a common
genetic determinant of fasting glucose levels in healthy,
diabetes-free individuals, is associated with measures of
beta cell function and whole-body insulin sensitivity.
Methods We studied 1,276 healthy individuals of European
ancestry at 19 centres of the Relationship between Insulin
Sensitivity and Cardiovascular disease (RISC) study. Whole-
body insulin sensitivity was assessed by euglycaemic–
hyperinsulinaemic clamp and indices of beta cell function
were derived from a 75 g oral glucose tolerance test (includ-
ing 30 min insulin response and glucose sensitivity). We
studied rs10830963 in MTNR1B using additive genetic
models, adjusting for age, sex and recruitment centre.
Results The minor (G) allele of rs10830963 in MTNR1B
(frequency 0.30 in HapMap Centre d’Etude du Polymor-
phisme [Utah residents with northern and western European
ancestry] [CEU]; 0.29 in RISC participants) was associated
with higher levels of fasting plasma glucose (standardised
beta [95% CI] 0.17 [0.085, 0.25] per G allele, p=5.8×10
−5),
consistent with recent observations. In addition, the G-allele
was significantly associated with lower early insulin
response (−0.19 [−0.28, −0.10], p=1.7×10
−5), as well as
with decreased beta cell glucose sensitivity (−0.11 [−0.20,
−0.027], p=0.010). No associations were observed with
clamp-assessed insulin sensitivity (p=0.15) or different
measures of body size (p>0.7 for all).
Conclusions/interpretation Genetic variation in MTNR1B is
associated with defective early insulin response and
decreased beta cell glucose sensitivity, which may con-
tribute to the higher glucose levels of non-diabetic
individuals carrying the minor G allele of rs10830963 in
MTNR1B.
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Introduction
Compared with recent progress in the discovery of genes
for type 2 diabetes, knowledge of genetic influences on
fasting glucose levels in healthy individuals is limited.
Common sequence variants related to the GCK promoter
[1–3], G6PC2 [2, 3]a n dGCKR [4–6]a r et h em o s t
significant determinants of fasting glucose levels identified
in recent large-scale genome-wide association studies
(GWAS), yet without demonstrable consistent effects on
the risk of type 2 diabetes [7]. Vice-versa, none of the
established type 2 diabetes genes have emerged as
convincing loci for fasting glucose within the normal range
in recent GWAS [2, 7]. This suggests that common variants
contributing to small physiological variation in fasting
glucose may be different from those that increase type 2
diabetes susceptibility.
One exception is noteworthy; in a recently published
exchange of top fasting glucose hits from four large GWAS
consortia, variants in the gene encoding the melatonin
receptor 1B (MTNR1B) were not only consistently associ-
ated with fasting glucose across all studies totalling 36,610
healthy adult participants in the meta-analysis of the
MTNR1B region [7], but carriers of the risk allele of the
most significant overall signal at rs10830963 (minor G
allele; frequency 0.30 in HapMap Centre d’Etude du
Polymorphisme [Utah residents with northern and western
European ancestry] [CEU]) were also at increased risk of
type 2 diabetes (odds ratio [95% CI] 1.09 [1.05, 1.12]) in a
separate meta-analysis of case–control studies [7]. The
novel link between MTNR1B and type 2 diabetes was
confirmed in two other studies, one investigating the same
variant [8], and another reporting rs1387153 (r
2 with
rs10830963=0.70) to be the most significant single
nucleotide polymorphism (SNP) in a GWAS of 2,151
French participants [2]. Investigating the mechanisms
through which MTNR1B contributes to variation in fasting
glucose levels in healthy, non-diabetic individuals may help
to understand what underlies the MTNR1B-related risk of
progression to clinical diabetes. Lyssenko et al. have
reported that the risk genotype was associated with
impairment of early insulin response to oral and intravenous
glucose, and with faster deterioration of insulin secretion
over time [8].
Thus our objective was to study whether the association
between MTNR1B and fasting glucose is mediated through
reduced pancreatic beta cell function, insulin secretion or
whole-body insulin sensitivity in individuals participating in the
Relationship between Insulin Sensitivity and Cardiovascular
disease (RISC) study [9].
Methods
The recruitment, methods, and inclusion and exclusion
criteria of the RISC cohort have been described previously
[9]. Briefly, healthy men and women of European ancestry,
aged between 30 and 60 years, were recruited from 19
centres in 14 European countries. Individuals with diabetes,
hypertension or dyslipidaemia were excluded [9]. Analyses
presented in this study are based on 1,276 participants who
met the eligibility criteria and for whom complete genotype
data were available. Local ethics committee approval was
obtained by each recruitment centre and written consent
was obtained from all participants.
Participants underwent a 75 g OGTT with blood sampling
before and at 30, 60, 90and120min after the oral glucose load.
On a separate day within 1 month of the OGTT, participants
underwent a euglycaemic–hyperinsulinaemic clamp as previ-
ously reported [9]. To ensure consistency across study centres,
the clamp procedure was standardised and each centre
underwent prestudy training. Clamp data were then transferred
and analysed at the RISC coordinating centre (Pisa, Italy) and
quality assured against preset criteria. These were as follows:
clamped glucose levels within 20% of target (fasting glucose
concentration), coefficient of variation of ≤15%, avoidance of
hypoglycaemia (glucose <3.5 mmol/l). Insulin sensitivity was
assessed as the mean glucose infusion rate over the last
40 min of the clamp, corrected for the mean plasma insulin
levels achieved during the same period. Pancreatic beta cell
function was assessed using the OGTT data. The 30 min
insulin response was calculated as the ratio of the insulin
concentration increment to the 30 min glucose concentration
(30 min insulin −0 min insulin/30 min glucose) [10]. We
additionally performed sensitivity analyses using other com-
monly derived indices of early insulin response, including
insulinogenic index (30 min insulin −0 min insulin/30 min
glucose −0 min glucose) and corrected insulin response [11].
Indices of beta cell function variables were derived from
mathematical analysis of plasma glucose and C-peptide,
using C-peptide deconvolution, as previously described in
more detail [12].
In addition, detailed anthropometric assessment was
performed and fat mass determined as the difference
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bioimpedance (Tanita International Division, Yiewsley, UK).
Samples were processed and stored locally before being
transferred to the central assay laboratories and analysed as
previously reported [9]. Genomic DNA was extracted using a
kit (Nucleon BACC2; Tepnel Life Sciences, Manchester, UK).
All samples were genotyped at KBiosciences (KBiosciences,
Hoddesdon, UK) [12]; the call rate was 98% and genotype
frequencies were in Hardy–Weinberg equilibrium (p=0.33).
Duplicate genotyping of 5% of DNA samples was conducted
with 100% success.
We normalised the distributions of OGTT and clamp
outcomes using the natural logarithm; these data are
presentedasmedianand interquartile range.Linearregression
analyses using an additive genetic model were performed to
test for associations between rs10830963 and selected
phenotypes, adjusting for age, sex and recruitment centre.
Standardised measures were used in regression analyses;
these were calculated by subtracting the mean of each
outcome from an individual’s value and dividing this by the
standard deviation, separately by sex, and using loge trans-
formed measures. This results in a normal distribution for
each measure with a mean of 0 and standard deviation of 1,
and allows the strength of the genotype effect to be
compared across several outcomes with different distribu-
tions and units. As previously reported [12], the cohort had
80% power at p=0.01 to detect differences of 0.18 SD per
allele for a minor allele frequency of 0.30.
Results
The minor (G) allele of rs10830963 was significantly
associated with higher fasting glucose levels (standardised
beta [95% CI] 0.17 [0.085, 0.25] per G allele, p=5.8×10
−5)
(Fig. 1a) consistent with recent observations [7]. In
addition, we observed significantly higher glucose levels
at 30 and 60 min (standardised beta [95% CI] 0.15 [0.065,
0.23], p=4.7×10
−4 and 0.13 [0.046, 0.21], p=2.3×10
−3,
respectively) (Fig. 1a), but not at 90 or 120 min during the
OGTT (p=0.21 and 0.93, respectively).
Variation at rs10830963 was not associated with whole-body
insulin sensitivity measured by euglycaemic–hyperinsulinaemic
clamps (standardised beta [95% CI] 0.064 [−0.024, 0.15],
p=0.15) (Fig. 2). In contrast, significant differences in indices
of pancreatic beta cell function were found. Individuals
carrying the minor (G) allele had significantly lower 30 min
insulin response (standardised beta [95% CI] −0.19 [−0.28,
−0.10], p=1.7×10
−5)( F i g .2), as well as beta cell glucose
sensitivity (standardised beta [95% CI] −0.11 [−0.20, −0.027],
p=0.010). These associations remained significant after addi-
tional adjustment for whole-body insulin sensitivity (p=0.0001
and 0.014 respectively). Similar results were obtained in
sensitivity analyses using the insulinogenic index (p=6.8×
10
−5) or corrected insulin response (p=2.7×10
−3) as alternative
measures of early insulin response. Associations with insulin
(Fig. 1b) and C-peptide (data not shown) mirrored these
observations, with the only time point during the OGTT at
which significant differences were found being at 30 min
(standardised beta [95% CI] −0.15 [−0.23, −0.061], p=8.0×
10
−4 for insulin; −0.089 [−0.17, −0.0044], p=0.039 for C-
peptide). No significant associations were observed between
variation in MTNR1B and different measures of body size
(Table 1).
Discussion
Recent evidence from large-scale meta-analysis of GWAS
showed that variation in MTNR1B is a common genetic
determinant of fasting glucose in healthy, diabetes-free
individuals. We show here that variation in MTNR1B is
significantly associated with early insulin response and beta
cell glucose sensitivity, while no effect on whole-body
insulin sensitivity was observed.
The minor (G) risk allele of rs10830963 in MTNR1B was
associated with lower beta cell glucose sensitivity and
30 min insulin response before and after accounting for
whole-body insulin sensitivity levels. These findings are in
keeping with a primary defect of beta cell function rather
than secondary changes in response to altered insulin
sensitivity, and support the observations of other studies,
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Fig. 1 Effect of rs10830963 in MTNR1B on glucose (a) and insulin
(b) levels during the OGTT (per allele difference and 95% CI). a
ap=
5.8×10
−5;
bp=4.7×10
−4;
cp=2.3×10
−3;
dp=0.211;
ep=0.926. b
ap=
0.135;
bp=8.0×10
−4;
cp=0.868;
dp=0.259;
ep=0.727
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decreased disposition index in G allele carriers of the same
variant [8, 13]. Interestingly, we found significant associ-
ations of rs10830963 with insulin and C-peptide at 30 min
during the OGTT, but not at any other time point, again
highlighting that the main effect appears to be on early-
phase insulin response. The emerging evidence strongly
suggests that the melatonin system directly modulates the
insulin secretory response to glucose. It has been shown
that MTNR1B is expressed in human islets, and specifically
in pancreatic beta and alpha cells [8, 14, 15]. Furthermore,
MTNR1B gene expression was increased in isolated islets
from older (>45 years of age) G allele carriers of
rs10830963, and exposure of clonal beta cells to melatonin
Table 1 Relationships between rs10830963 genotypes and key phenotypic traits
Phenotype Mean (SD)/median (IQR) Mean (SD), median (IQR) by genotype p value
CC (max n=655) GC (max n=505) GG (max n=114)
Sex (% women) 55.2 58.0 54.0 43.9 0.016
Age (years) 43.9 (8.3) 44 (8.2) 44 (8.2) 43 (9.3) 0.34
BMI (kg/m
2) 25.7 (4.1) 25.5 (4.0) 25.6 (4.1) 25.8 (4.1) 0.81
Waist (cm) 86 (77–96) 85 (76–95) 86 (78–96) 88 (79–96) 0.93
Fat mass (kg) 21.2 (8.9) 21.2 (8.9) 21.0 (8.9) 20.2 (9.2) 0.78
Glucose (mmol/l)
OGTT 0 min (fasting) 5.1 (4.7–5.4) 5.0 (4.7–5.3) 5.1 (4.8–5.5) 5.2 (4.8–5.5) 5.8×10
−5
OGTT 30 min 8.0 (6.9–9.3) 7.8 (6.7–8.9) 8.2 (7.1–9.4) 7.9 (7.0–9.5) 4.7×10
−4
OGTT 60 min 7.5 (6.0–9.3) 7.2 (5.8–8.8) 7.8 (6.3–9.4) 7.7 (6.1–9.7) 2.3×10
−3
OGTT 90 min 6.2 (5.0–7.5) 6.1 (5.0–7.3) 6.4 (5.2–7.7) 6.2 (5.1–7.6) 0.21
OGTT 120 min 5.6 (4.7–6.7) 5.6 (4.7–6.6) 5.6 (4.6–6.6) 5.5 (4.6–6.9) 0.93
Insulin (pmol/l)
OGTT 0 min (fasting) 31.0 (21.0–46.0) 31.0 (21.0–44.0) 31.0 (21.0–45.5) 28.5 (19.0–42.0) 0.32
OGTT 30 min 240 (168–355) 244 (173–358) 238 (167–347) 199 (152–297) 8.0×10
−4
OGTT 60 min 269 (178–413) 265 (172–399) 266 (177–406) 244 (166–385) 0.87
OGTT 90 min 200 (127–316) 196 (122–309) 210 (136–330) 197 (123–295) 0.26
OGTT 120 min 153 (89–257) 147 (89–249) 151 (85–251) 159 (73–226) 0.73
C-peptide (pmol/l)
OGTT 0 min (fasting) 540 (410–703) 528 (399–690) 562 (420–727) 525 (391–682) 0.88
OGTT 30 min 1,891 (1,502–2,387) 1,910 (1,517–2,403) 1,894 (1,511–2,391) 1,704 (1,416–2,095) 0.039
OGTT 60 min 2,509 (2,008–3,098) 2,440 (1,961–3,029) 2,558 (2,066–3,182) 2,562 (1,927–3,022) 0.78
OGTT 90 min 2,406 (1,863–3,036) 2,336 (1,789–2,958) 2,509 (1,955–3,116) 2,512 (1,843–3,148) 0.24
OGTT 120 min 2,154 (1,642–2,777) 2,121 (1,598–2,743) 2,213 (1,677–2,789) 2,252 (1,603–2,777) 0.56
30 min insulin response (pmol/mmol) 26.3 (18.5–38.7) 28.0 (19.3–41.4) 25.9 (18.4–37.0) 22.0 (14.9–33.8) 1.7×10
−5
Beta cell glucose sensitivity
a 113 (79–158) 118 (82–169) 109 (74–150) 102 (74–148) 0.010
Insulin sensitivity
b 128 (92–177) 128 (90–175) 128 (92–180) 135 (99–175) 0.15
Comparisons between genotypes (additive model) are based on linear regression analysis of loge-transformed data (where applicable) and using
sex-specific standardised outcomes for OGTT and clamp measures, adjusting for age, sex and recruitment centre
Sex differences were tested using a χ
2 test
aIn pmol min
−1 m
−2 mmol
−1
bIn μmol min
−1 (kg fat-free mass)
−1 nmol
−1
IQR, interquartile range
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Fig. 2 Effect of rs10830963 in MTNR1B on early insulin response,
beta cell glucose sensitivity and whole-body insulin sensitivity (M/I)
(per allele difference and 95% CI).
ap=1.7×10
−5;
bp=0.010;
cp=0.154
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[8]. It has also been postulated that melatonin might
influence insulin secretion through a paracrine effect of
glucagon [14]. We found that variation in MTNR1B was not
associated with fasting glucagon levels (data not shown),
but we did not measure the glucagon response during the
OGTT.
Melatonin plays a role in regulation of the circadian
clock, and melatonin and insulin both show marked
circadian variability [16, 17]. Data from human and rodent
studies suggest that disturbances of circadian rhythmicity
may affect metabolic control and the risk of diabetes [18,
19]. Moreover, overexpression of melatonin receptors has
been observed in islets from patients with type 2 diabetes
compared with non-diabetic controls [20]. Taken together,
these findings suggest that an effect of MTNR1B on the
insulin secretory response to glucose may underlie the
reported associations with fasting glucose and the risk of
type 2 diabetes, adding to the body of evidence linking
circadian rhythm and metabolic control and disease.
A key observation of our study is that there was no
significant association between the MTNR1B variant and
whole-body insulin sensitivity, despite the fact that this is
one of the largest collections of healthy people of European
ancestry to be phenotyped using the gold standard
euglycaemic–hyperinsulinaemic clamp technique. In addi-
tion, we have replicated with the RISC cohort the observa-
tions that a common FTO variant and the Pro12Ala PPARG
variant influence whole-body insulin sensitivity in man [12].
This would suggest that if variation in MTNR1B does affect
insulin sensitivity, then it is likely to be functionally weak
and of questionable clinical significance. In support of this,
Staiger et al. recently reported that none of five tagging
SNPs covering all common genetic variation of the MTNR1B
locus showed an association with clamp-derived insulin
sensitivity in a selected group of 513 individuals at increased
risk of type 2 diabetes [13].
We also found no significant associations between
MTNR1B and different measures of body size, suggesting
that the effects seen on beta cell function are not influenced
by an alteration in adiposity.
As we recently reported, individual type 2 diabetes risk
alleles in TCF7L2, HHEX, IDE and CDKAL1 combine in
an additive manner to impact upon pancreatic beta cell
function [21]. Beta cell glucose sensitivity was decreased
by 39% in individuals with five or more risk alleles
compared with individuals who had no risk alleles.
Inclusion of the MTNR1B risk variant in the analysis led
to a 47% difference (p=1.5×10
−7) between the zero-allele
group those with more than six alleles. A similar change
was noted for the 30 min insulin response. We had
previously found a 43% decrease between the zero-allele
group and the group with more than five alleles. Inclusion
of the MTNR1B variant increased that value to 49%
between the zero-allele group and those with more than
six alleles.
We conclude that MTNR1B is associated with defective
early insulin response and decreased beta cell glucose
sensitivity, both of which may contribute to the higher
glucose levels and increased diabetes risk of individuals
carrying the minor G allele of rs10830963. In contrast, no
association with whole-body insulin sensitivity was observed
in this large collection of healthy people of European ancestry.
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